These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 25003953)
21. Potent antiplatelet activity of sesamol in an in vitro and in vivo model: pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase. Chang CC; Lu WJ; Chiang CW; Jayakumar T; Ong ET; Hsiao G; Fong TH; Chou DS; Sheu JR J Nutr Biochem; 2010 Dec; 21(12):1214-21. PubMed ID: 20015631 [TBL] [Abstract][Full Text] [Related]
22. p-Terphenyl curtisian E inhibits in vitro platelet aggregation via cAMP elevation and VASP phosphorylation. Kamruzzaman SM; Yayeh T; Ji HD; Park JY; Kwon YS; Lee IK; Kim S; Oh SH; Kim SD; Roh SS; Yun BS; Rhee MH Vascul Pharmacol; 2013; 59(3-4):83-9. PubMed ID: 23872194 [TBL] [Abstract][Full Text] [Related]
23. Prostaglandin E2 levels and platelet function are different in cord blood compared to adults. Schlagenhauf A; Haidl H; Leschnik B; Leis HJ; Heinemann A; Muntean W Thromb Haemost; 2015 Jan; 113(1):97-106. PubMed ID: 25118631 [TBL] [Abstract][Full Text] [Related]
24. Decreased VASP phosphorylation in platelets of male and female smokers of young age. Assinger A; Schmid W; Volf I Platelets; 2010; 21(8):596-603. PubMed ID: 20822337 [TBL] [Abstract][Full Text] [Related]
25. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease. Heptinstall S; Espinosa DI; Manolopoulos P; Glenn JR; White AE; Johnson A; Dovlatova N; Fox SC; May JA; Hermann D; Magnusson O; Stefansson K; Hartman D; Gurney M Platelets; 2008 Dec; 19(8):605-13. PubMed ID: 19012178 [TBL] [Abstract][Full Text] [Related]
26. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions. Bilodeau ML; Hamm HE J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299 [TBL] [Abstract][Full Text] [Related]
27. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Meja KK; Barnes PJ; Giembycz MA Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541 [TBL] [Abstract][Full Text] [Related]
28. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. Fabre JE; Nguyen M; Athirakul K; Coggins K; McNeish JD; Austin S; Parise LK; FitzGerald GA; Coffman TM; Koller BH J Clin Invest; 2001 Mar; 107(5):603-10. PubMed ID: 11238561 [TBL] [Abstract][Full Text] [Related]
29. Prostaglandin F2α Facilitates Platelet Activation by Acting on Prostaglandin E2 Receptor Subtype EP3 and Thromboxane A2 Receptor TP in Mice. Kashiwagi H; Yuhki KI; Imamichi Y; Kojima F; Kumei S; Tasaki Y; Narumiya S; Ushikubi F Thromb Haemost; 2019 Aug; 119(8):1311-1320. PubMed ID: 31129913 [TBL] [Abstract][Full Text] [Related]
30. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion. Hornby EJ; Foster MR; McCabe PJ; Stratton LE Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661 [TBL] [Abstract][Full Text] [Related]
31. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change. Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F Platelets; 2011; 22(1):8-19. PubMed ID: 20958117 [TBL] [Abstract][Full Text] [Related]
33. Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes. Aso H; Ito S; Mori A; Suganuma N; Morioka M; Takahara N; Kondo M; Hasegawa Y Am J Respir Cell Mol Biol; 2013 Mar; 48(3):322-9. PubMed ID: 23221043 [TBL] [Abstract][Full Text] [Related]
34. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase. Liu FC; Liao CH; Chang YW; Liou JT; Day YJ Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675 [TBL] [Abstract][Full Text] [Related]
35. Dynamical modelling of prostaglandin signalling in platelets reveals individual receptor contributions and feedback properties. Mischnik M; Hubertus K; Geiger J; Dandekar T; Timmer J Mol Biosyst; 2013 Oct; 9(10):2520-9. PubMed ID: 23903629 [TBL] [Abstract][Full Text] [Related]
36. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor. Dovlatova N; Wijeyeratne YD; Fox SC; Manolopoulos P; Johnson AJ; White AE; Latif ML; Ralevic V; Heptinstall S Thromb Haemost; 2008 Aug; 100(2):261-70. PubMed ID: 18690346 [TBL] [Abstract][Full Text] [Related]
37. Prostaglandin receptors on human platelets. Structure-activity relationships of stimulatory prostaglandins. MacIntyre DE; Salzman EW; Gordon JL Biochem J; 1978 Sep; 174(3):921-9. PubMed ID: 215124 [TBL] [Abstract][Full Text] [Related]
38. Interaction of prostaglandins E1 and E2 in regulation of cyclic-AMP and aggregation in human platelets: evidence for a common prostaglandin receptor. McDonald JW; Stuart RK J Lab Clin Med; 1974 Jul; 84(1):111-21. PubMed ID: 4365532 [TBL] [Abstract][Full Text] [Related]
39. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents. Manolopoulos P; Glenn JR; Fox SC; May JA; Dovlatova NL; Tang SW; Thomas NR; Ralevic V; Heptinstall S Platelets; 2008 Mar; 19(2):134-45. PubMed ID: 18297551 [TBL] [Abstract][Full Text] [Related]
40. Functional pharmacology of human prostanoid EP2 and EP4 receptors. Wilson RJ; Rhodes SA; Wood RL; Shield VJ; Noel LS; Gray DW; Giles H Eur J Pharmacol; 2004 Oct; 501(1-3):49-58. PubMed ID: 15464062 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]